Y-mAbs Therapeutics, Inc. Selling, General and Administrative Expense
Y-mAbs Therapeutics, Inc. reported Selling, General and Administrative Expense of $11.31 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-08-08
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $11.31M, a 34.35% decline year-over-year.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-03-31 was $13.09M, a 14.55% increase year-over-year.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2024-12-31 was $12.38M, a 11.14% increase year-over-year.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2024-09-30 was $13.61M, a 33.46% increase year-over-year.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for fiscal 2024 was $54.65M, a 21.82% increase from fiscal 2023.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for fiscal 2023 was $44.86M, a 26.39% decline from fiscal 2022.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for fiscal 2022 was $60.94M, a 11.67% increase from fiscal 2021.
- Y-mAbs Therapeutics, Inc. selling, general and administrative expense for fiscal 2021 was $54.57M, a 21.85% increase from fiscal 2020.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $11.31M 10-Q · filed 2025-08-08 | $24.40M 10-Q · filed 2025-08-08 | $36.77M derived: sum of 3 quarters · filed 2025-08-08 | $50.39M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $13.09M 10-Q · filed 2025-05-13 | $25.46M derived: sum of 2 quarters · filed 2025-05-13 | $39.08M derived: sum of 3 quarters · filed 2025-05-13 | $56.31M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-12-31 | $12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $25.99M derived: sum of 2 quarters · filed 2025-03-04 | $43.22M derived: sum of 3 quarters · filed 2025-08-08 | $54.65M 10-K · filed 2025-03-04 |
| 2024-09-30 | $13.61M 10-Q · filed 2024-11-08 | $30.84M derived: sum of 2 quarters · filed 2025-08-08 | $42.27M 10-Q · filed 2024-11-08 | $53.41M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-06-30 | $17.23M 10-Q · filed 2025-08-08 | $28.66M 10-Q · filed 2025-08-08 | $39.79M derived: sum of 3 quarters · filed 2025-08-08 | $49.99M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $11.43M 10-Q · filed 2025-05-13 | $22.56M derived: sum of 2 quarters · filed 2025-05-13 | $32.76M derived: sum of 3 quarters · filed 2025-05-13 | $44.03M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $11.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $21.34M derived: sum of 2 quarters · filed 2025-03-04 | $32.60M derived: sum of 3 quarters · filed 2025-03-04 | $44.86M 10-K · filed 2025-03-04 |
| 2023-09-30 | $10.20M 10-Q · filed 2024-11-08 | $21.47M derived: sum of 2 quarters · filed 2024-11-08 | $33.72M 10-Q · filed 2024-11-08 | $44.51M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $11.27M 10-Q · filed 2024-08-12 | $23.52M 10-Q · filed 2024-08-12 | $34.31M derived: sum of 3 quarters · filed 2024-08-12 | $47.94M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $12.25M 10-Q · filed 2024-05-07 | $23.04M derived: sum of 2 quarters · filed 2024-05-07 | $36.67M derived: sum of 3 quarters · filed 2024-05-07 | $59.75M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $24.42M derived: sum of 2 quarters · filed 2024-02-29 | $47.50M derived: sum of 3 quarters · filed 2024-02-29 | $60.94M 10-K · filed 2024-02-29 |
| 2022-09-30 | $13.63M 10-Q · filed 2023-11-13 | $36.71M derived: sum of 2 quarters · filed 2023-11-13 | $50.15M 10-Q · filed 2023-11-13 | $65.28M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $23.08M 10-Q · filed 2023-08-10 | $36.52M 10-Q · filed 2023-08-10 | $51.66M derived: sum of 3 quarters · filed 2023-08-10 | $65.65M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.44M 10-Q · filed 2023-05-08 | $28.58M derived: sum of 2 quarters · filed 2023-05-08 | $42.56M derived: sum of 3 quarters · filed 2023-05-08 | $56.04M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $29.13M derived: sum of 2 quarters · filed 2023-03-30 | $42.60M derived: sum of 3 quarters · filed 2023-03-30 | $54.57M 10-K · filed 2023-03-30 |
| 2021-09-30 | $13.99M 10-Q · filed 2022-11-07 | $27.46M derived: sum of 2 quarters · filed 2022-11-07 | $39.43M 10-Q · filed 2022-11-07 | $54.06M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $13.47M 10-Q · filed 2022-08-08 | $25.45M 10-Q · filed 2022-08-08 | $40.08M derived: sum of 3 quarters · filed 2022-08-08 | $51.71M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $11.97M 10-Q · filed 2022-05-09 | $26.60M derived: sum of 2 quarters · filed 2022-05-09 | $38.24M derived: sum of 3 quarters · filed 2022-05-09 | $48.63M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $14.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $26.27M derived: sum of 2 quarters · filed 2022-03-01 | $36.66M derived: sum of 3 quarters · filed 2022-03-01 | $44.78M 10-K · filed 2022-03-01 |
| 2020-09-30 | $11.64M 10-Q · filed 2021-11-04 | $22.03M derived: sum of 2 quarters · filed 2021-11-04 | $30.16M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $10.39M 10-Q · filed 2021-08-09 | $18.52M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $8.13M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $19.51M 10-K · filed 2022-03-01 |